Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CARM1 | Q86X55 | 2/20 | 0.74 |
| ▸ | PRMT6 | Q96LA8 | 2/20 | 0.74 |
| ▸ | ACHE | P22303 | 12/20 | 0.69 |
| ▸ | BACE1 | P56817 | 12/20 | 0.69 |
| ▸ | BCHE | P06276 | 9/20 | 0.69 |
| ▸ | MEN1 | O00255 | 3/20 | 0.65 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.65 |
| ▸ | DRD2 | P14416 | 1/20 | 0.55 |
| ▸ | FABP6 | P51161 | 1/20 | 0.53 |
| ▸ | RAB9A | P51151 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18658247 | 0.91 | CARM1 (0.70) | CARM1PRMT6ACHEBACE1BCHE | |
| SCHEMBL20492896 | 0.90 | CARM1 (0.68) | CARM1PRMT6ACHEBACE1BCHE | |
| SCHEMBL20492895 | 0.88 | CARM1 (0.67) | CARM1PRMT6ACHEBACE1BCHE | |
| SCHEMBL5272937 | 0.86 | ACHE (0.71) | CARM1PRMT6ACHEBACE1BCHE | |
| SCHEMBL18640249 | 0.85 | CARM1 (0.55) | CARM1PRMT6ACHEBACE1BCHE | |
| SCHEMBL20492718 | 0.84 | CARM1 (0.68) | CARM1PRMT6ACHEBACE1BCHE | |
| SCHEMBL20492779 | 0.84 | CARM1 (0.68) | CARM1PRMT6ACHEBACE1BCHE | |
| SCHEMBL8081164 | 0.83 | ACHE (0.68) | CARM1PRMT6ACHEBACE1BCHE | |
| SCHEMBL18640339 | 0.83 | KDM4E (0.62) | CARM1PRMT6ACHEBACE1BCHE | |
| SCHEMBL28249235 | 0.82 | ACHE (0.68) | CARM1PRMT6ACHEBACE1BCHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12605373-B2 | Methods and compositions of inhibiting DCN1-UBC12 interaction | MEMORIAL SLOAN KETTERING CANCER CENTER (US) | 2026-04-21 | — | — | US | disclosed |
| US-20250120965-A1 | METHODS AND COMPOSITIONS OF INHIBITING DCN1-UBC12 INTERACTION | MEMORIAL SLOAN KETTERING CANCER CENTER (US) | 2025-04-17 | — | — | US | disclosed |
| US-11963954-B2 | Methods and compositions of inhibiting DCN1-UBC12 interaction | MEMORIAL SLOAN KETTERING CANCER CENTER (US) | 2024-04-23 | — | — | US | disclosed |
| US-20230021224-A1 | METHODS AND COMPOSITIONS OF INHIBITING DCN1-UBC12 INTERACTION | MEMORIAL SLOAN KETTERING CANCER CENTER (US) | 2023-01-19 | — | — | US | disclosed |
| EP-3349743-B1 | METHODS AND COMPOSITIONS OF INHIBITING DCN1-UBC12 INTERACTION | ST JUDE CHILDRENS RES HOSPITAL (US) | 2022-04-06 | — | — | EP | disclosed |
| US-11116757-B2 | Methods and compositions of inhibiting DCN1-UBC12 interaction | MEMORIAL SLOAN KETTERING CANCER CENTER (US) | 2021-09-14 | — | — | US | disclosed |
| US-20210069172-A1 | METHODS AND COMPOSITIONS OF INHIBITING DCN1-UBC12 INTERACTION | MEMORIAL SLOAN KETTERING CANCER CENTER (US) | 2021-03-11 | — | — | US | disclosed |
| US-20180256558-A1 | METHODS AND COMPOSITIONS OF INHIBITING DCN1-UBC12 INTERACTION | MEMORIAL SLOAN KETTERING CANCER CENTER (US) | 2018-09-13 | — | — | US | disclosed |
| US-7576105-B2 | Benzyl substituted (piperidin-4-yl)aminobenzamido derivatives | JANSSEN PHARMACEUTICA, NV (BE) | 2009-08-18 | — | — | US | disclosed |
| US-7576105-B2 | Benzyl substituted (piperidin-4-yl)aminobenzamido derivatives | JANSSEN PHARMACEUTICA, NV (BE) | 2009-08-18 | — | — | US | disclosed |
| US-20060106066-A1 | Benzyl substituted (piperidin-4-yl)aminobenzamido derivatives | BAXTER ELLEN W | 2006-05-18 | — | — | US | disclosed |
| WO-2004035541-A1 | BENZYL SUBSTITUTED (PIPERIDIN-4-YL) AMINOBENZAMIDO DERIVATIVES AS DELTA-OPIOD RECEPTOR MODULATORS | JANSSEN PHARMACEUTICA, N.V. (BE) | 2004-04-29 | — | — | WO | disclosed |
| US-20040082612-A1 | Benzyl substituted (piperidin-4-yl)aminobenzamido derivatives | JANSSEN PHARMACEUTICALS N.V. (BE) | 2004-04-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180256558-A1 | METHODS AND COMPOSITIONS OF INHIBITING DCN1-UBC12 INTERACTION | UBQLN1, CUL1, DCUN1D1 | CARM1 863/4885PRMT6 1045/4885ACHE 3169/4885 |
| US-20060106066-A1 | Benzyl substituted (piperidin-4-yl)aminobenzamido derivatives | OPRD1, OPRK1, OPRM1 | CARM1 1756/4885PRMT6 1096/4885ACHE 1259/4885 |
| US-12605373-B2 | Methods and compositions of inhibiting DCN1-UBC12 interaction | CUL3, CUL1, CUL5 | CARM1 962/4885PRMT6 1459/4885ACHE 4566/4885 |
| US-20040082612-A1 | Benzyl substituted (piperidin-4-yl)aminobenzamido derivatives | OPRD1, OPRK1, OPRM1 | CARM1 1756/4885PRMT6 1096/4885ACHE 1259/4885 |
| US-20230021224-A1 | METHODS AND COMPOSITIONS OF INHIBITING DCN1-UBC12 INTERACTION | UBQLN1, CUL1, DCUN1D1 | CARM1 863/4885PRMT6 1045/4885ACHE 3169/4885 |
| US-11116757-B2 | Methods and compositions of inhibiting DCN1-UBC12 interaction | UBQLN1, CUL1, DCUN1D1 | CARM1 863/4885PRMT6 1045/4885ACHE 3169/4885 |
| US-11963954-B2 | Methods and compositions of inhibiting DCN1-UBC12 interaction | UBQLN1, CUL1, DCUN1D1 | CARM1 863/4885PRMT6 1045/4885ACHE 3169/4885 |
| US-20210069172-A1 | METHODS AND COMPOSITIONS OF INHIBITING DCN1-UBC12 INTERACTION | UBQLN1, CUL1, DCUN1D1 | CARM1 863/4885PRMT6 1045/4885ACHE 3169/4885 |
| US-20250120965-A1 | METHODS AND COMPOSITIONS OF INHIBITING DCN1-UBC12 INTERACTION | UBQLN1, CUL1, DCUN1D1 | CARM1 863/4885PRMT6 1045/4885ACHE 3169/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.